CAS 1092578-46-5

Formule : C16H20N6O

InChI : InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13-/m0/s1

Code InChI : UJLAWZDWDVHWOW-AAEUAGOBSA-N

SMILES : C[C@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

3-((3R,4S)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

CAS : 1092578-46-5

3-((3R,4S)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

Formule : C₁₆H₂₀N₆O

Degré de pureté : 98%

Masse moléculaire : 312.38

Ref: 54-OR1073772

(3R,4S)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile

CAS : 1092578-46-5

Formule : C₁₆H₂₀N₆O

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 312.3696

Ref: IN-DA008T9A

Tofacitinib Impurity 42

CAS : 1092578-46-5

Formule : C₁₆H₂₀N₆O

Couleur et forme : White To Off-White Solid

Masse moléculaire : 312.38

Ref: 4Z-T-117003

(3R,4S)-Tofacitinib

CAS : 1092578-46-5

3-((3R,4S)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

Formule : C₁₆H₂₀N₆O

Degré de pureté : 98%

Masse moléculaire : 312.37

Ref: IN-DG491021

(3R,4S)-Tofacitinib

Produit contrôlé

CAS : 1092578-46-5

Applications (3R,4S)-Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases.
References Jiang, J., et. al.: J. med. Chem., 51, 8012 (2008)

Formule : C₁₆H₂₀N₆O

Couleur et forme : Neat

Masse moléculaire : 312.37

Ref: TR-T528000

(3R,4S)-Tofacitinib-d3

Produit contrôlé

CAS : 1092578-46-5

Formule : C₁₆D₃H₁₇N₆O

Couleur et forme : Neat

Masse moléculaire : 315.388

Ref: TR-T528002

(3R,4S)-Tofacitinib

CAS : 1092578-46-5

Formule : C₁₆H₂₀N₆O

Masse moléculaire : 312.38

Ref: ST-EA-CP-T23039

(3R,4S)-Tofacitinib

CAS : 1092578-46-5

(3R,4S)-Tofacitinib is a synthetic compound that is being researched for the treatment of rheumatoid arthritis. It is a potent inhibitor of Janus Kinase 3 (JAK3) and Janus Kinase 1 (JAK1), which are important enzymes in cytokine signaling pathways that play a role in inflammation. (3R,4S)-Tofacitinib is metabolized to an impurity standard for the drug product. The metabolite has not been characterized and its concentration cannot be determined from analytical data.

Formule : C₁₆H₂₀N₆O

Degré de pureté : Min. 95%

Masse moléculaire : 312.37 g/mol

Ref: 3D-STB57846